1363-P: Diabetes Control and Complications in West India—Three-Year Results of LANDMARC Trial

Glycemic control, therapy trends, and diabetes complications were evaluated in LANDMARC — a prospective observational 3-year study (CTRI/2017/05/008452) of participants with T2D on ≥2 antihyperglycemic medications. This sub-analysis of 81 sites in West India (Ahmedabad, Mumbai, and Pune) included 1351 participants (mean [SD] baseline [BL] age: 53.2 [9.1] years, T2D duration: 8.9 [5.8] years and A1C: 7.9% [1.5]). At BL, most were insulin-naïve (n=1037; 77.4%), mainly on OADs (n=1013; 76.9%). At 3 years, 68.2% (n=733) were on OADs only, while 29.8% (n=320) were on insulin + OADs. Biguanides was the most prescribed class (BL: 1253 [93.5%] and 3-years: 1007 [93.7%]). Basal insulin usage increased from BL (n=203; 15.2%) to 3 years (n=237; 22.1%). Mean (SD) A1C, FPG, and PPG decreased by 0.4 (1.5) %, 7.2 (48.2) mg/dL, and 16.5 (73.8) mg/dL, respectively; and an increase in proportion of participants with A1C